Ainos, Inc. (NASDAQ:AIMD) Short Interest Down 46.6% in October

Ainos, Inc. (NASDAQ:AIMD) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totaling 12,400 shares, a drop of 46.6% from the September 30th total of 23,200 shares. Currently, 0.6% of the shares of the stock are sold short. Based on an average trading volume of 2,260,000 shares, the short-interest ratio is presently 0.0 days. Based on an average trading volume of 2,260,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.6% of the shares of the stock are sold short.

Ainos Trading Down 2.1%

Shares of AIMD stock opened at $3.30 on Friday. The company has a market capitalization of $15.74 million, a P/E ratio of -0.66 and a beta of 2.25. Ainos has a 12-month low of $2.00 and a 12-month high of $5.00. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 0.96. The firm has a 50-day moving average price of $3.68 and a 200 day moving average price of $3.15.

Ainos (NASDAQ:AIMD) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.99) earnings per share for the quarter.

Insider Activity at Ainos

In other news, major shareholder Carbon Nano Technology Taiwan sold 7,000 shares of Ainos stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $3.59, for a total transaction of $25,130.00. Following the sale, the insider directly owned 1,037,206 shares in the company, valued at approximately $3,723,569.54. The trade was a 0.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.79% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on AIMD. Weiss Ratings restated a “sell (d-)” rating on shares of Ainos in a research note on Tuesday, October 14th. Wall Street Zen raised Ainos from a “sell” rating to a “hold” rating in a report on Friday, September 5th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Ainos Company Profile

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.